Polymyalgia Rheumatica: Symptoms, Diagnosis and Care

This guide explains how polymyalgia rheumatica is assessed, what treatment decisions involve and which changes need urgent help. It also suggests practical questions about daily function and ongoing care. Sources were checked on 9 October 2026.

What polymyalgia rheumatica can feel like

Polymyalgia rheumatica, usually shortened to PMR, is an inflammatory condition that causes aching and stiffness, particularly around the shoulders and hips. It almost always begins after age 50. Symptoms can make getting out of bed, dressing or lifting the arms difficult. The discomfort often increases after rest and is particularly noticeable on waking. PMR is closely associated with giant cell arteritis, an inflammatory disease of the arteries. Understanding that connection is part of learning about PMR, even when shoulder and hip symptoms are the main reason for seeking help. [3]

A useful symptom description includes both location and timing. Are both shoulders affected? Is turning in bed difficult? Does stiffness return after sitting through a meal or a car journey? PMR symptoms can develop quickly and commonly affect both sides, although the experience is not identical for everyone. Sleep, dressing and getting up from a chair can all be disrupted. These practical examples help communicate the effect of illness more clearly than saying only that the muscles hurt. Record what has changed from usual ability, including activities that now require help. [2]

PMR can affect confidence and independence as well as movement. In interviews with people living with the condition, disability, uncertainty and feeling vulnerable were prominent concerns. Some participants still had troublesome symptoms despite treatment, challenging the idea that everyone immediately feels completely normal. That does not mean persistent symptoms should simply be accepted. It means they deserve a fuller discussion: which tasks remain difficult, whether sleep is disrupted and whether the person is avoiding activities through fear or pain. Describing these effects helps the care team understand what recovery would mean beyond a better blood-test result. [16]

Why giant cell arteritis changes the urgency

Giant cell arteritis does not always produce a classic headache. Inflammation may involve the aorta or other large arteries, and some people have general illness or limb discomfort without prominent head or scalp symptoms. That is one reason a clinician considers the whole history rather than checking only for temple pain. New unexplained symptoms should be reported during follow-up. A person already taking PMR treatment should still seek urgent assessment for the warning signs described above; the existence of a prescription does not establish that a new problem is covered. [3]

EULAR’s 2025 recommendations, published in July 2026, bring PMR and large-vessel vasculitis into one management framework. They recommend specialist assessment for suspected PMR and an urgent pathway for suspected giant cell arteritis, with assessment within 24 hours. When suspicion of giant cell arteritis is strong, treatment should not wait for confirmatory investigations. This is a clinician-led decision because preventing complications and arranging reliable testing must happen together. For patients, the practical message is to explain new head, jaw or visual symptoms clearly when contacting a service, rather than describing the problem only as a return of shoulder pain. [4]

How clinicians assess a possible diagnosis

Assessment begins with the symptom history and examination, including consideration of rheumatoid arthritis, shoulder tendon problems, osteoarthritis, infection, thyroid disease, inflammatory muscle disease, medicine-related muscle symptoms and some cancers. Depending on the findings, baseline investigations may include a blood count, kidney and liver tests, glucose and rheumatoid antibodies, with thyroid or muscle-enzyme tests when relevant. This is not a universal shopping list to order independently. Unexplained weight loss, persistent fever, true loss of muscle strength or an unusual pattern needs assessment rather than automatic attribution to PMR. The aim is to identify plausible alternatives and establish useful information before longer-term treatment. [38]

Research classification criteria help investigators assemble comparable groups, but they are not a self-diagnosis checklist. The 2012 EULAR/ACR criteria were developed in people with new symptoms and comparison conditions that resembled PMR. They consider features such as age, bilateral shoulder pain, morning stiffness and inflammation tests, with ultrasound sometimes adding information. Even in that study, the criteria did not perfectly distinguish PMR from other conditions, especially rheumatoid arthritis. A person should not calculate a score online and treat it as proof. Clinical diagnosis also depends on alternative explanations and how the picture develops over time. [13]

Inflammatory blood tests are useful pieces of evidence, not a complete verdict. A small retrospective study described patients assessed as having PMR despite normal erythrocyte sedimentation rate and C-reactive protein results, using clinical assessment and imaging in their evaluation. The study cannot tell us how often that occurs in every setting, and normal results make careful consideration of other diagnoses particularly important. Equally, a raised result does not identify the cause by itself. Ask what the tests add to the assessment and what the next step is if the symptoms and laboratory findings do not agree. [29]

Why the diagnosis may need revisiting

Rheumatoid arthritis beginning later in life can initially resemble PMR. In a prospective study of people presenting with shoulder and hip girdle symptoms, some initially thought to have PMR were diagnosed with rheumatoid arthritis during follow-up. The study’s selected population is not a forecast of what will happen to every patient, but it illustrates why reassessment matters. New persistent swelling in the hands, wrists or other joints should be described rather than dismissed as part of the original label. A diagnosis can become clearer as the pattern evolves, and changing it in response to evidence is appropriate care. [14]

Calcium pyrophosphate crystal disease is another possible mimic, particularly when painful or swollen peripheral joints accompany shoulder or hip symptoms. Research following people with PMR-like symptoms found that the pattern of joint involvement and imaging could help identify this alternative. Calcification on an image is not automatically the explanation for every ache, however, and two conditions can coexist. Tell the clinician about episodes of sudden joint swelling and previous imaging or joint-fluid results. The assessment should connect those findings to the current symptoms, rather than assuming that any single abnormal scan settles the diagnosis. [15]

Improvement after glucocorticoids can support an assessment, but it does not prove PMR. These medicines suppress inflammation and may temporarily improve or mask other disorders. Patients also differ in the speed and completeness of response. A disappointing response should prompt review of the diagnosis and treatment plan, not an unsupervised increase. During follow-up, the important question is whether the overall course still makes sense, including persistent problems and anything new. [38]

What shoulder, hip and specialist scans can add

Ultrasound can look for inflammation around the shoulders and hips, including fluid-filled structures called bursae. An Italian case-control study found shoulder bursitis much more often in PMR than in comparison patients, but results from a selected study population cannot establish certainty for every patient. A scan therefore supports a clinical assessment rather than replacing it. The question is whether the pattern fits the symptoms and helps distinguish realistic alternatives. A normal scan or a single abnormality should not be interpreted from its report in isolation. Ask the clinician what the result changes about the diagnosis or treatment plan. [19]

MRI can reveal inflammation around tendons, joint capsules and other soft tissues that is less apparent on a routine examination. Pelvic MRI studies have described patterns associated with PMR, but those studies involved selected patients and comparison groups. They do not make MRI a required test for every person with typical symptoms. A useful reason for additional imaging is a specific unresolved question, such as whether another explanation for pain is more likely. Ask what the proposed scan can show, what it cannot settle and whether the result is expected to change care. [20]

In selected specialist assessments, PET/CT can examine patterns of inflammation in several body areas, including large blood vessels. It may be helpful when the diagnosis is uncertain or arterial involvement is being considered. The interpretation depends on the clinical question and on treatment already received, because glucocorticoids can affect scan findings. Report the actual medicines and when they were started. Never pause steroids or reproduce a study’s scan-preparation instructions independently. The treating team must balance the need for timely treatment with obtaining useful information, especially when giant cell arteritis is suspected. [21]

Tests used when giant cell arteritis is suspected

Tests for suspected giant cell arteritis follow a different pathway from investigating ordinary shoulder pain. EULAR imaging guidance recommends ultrasound first where appropriate expertise is available, including assessment of the axillary arteries in the armpits as well as the temporal arteries. MRI or PET may be alternatives in suitable circumstances. The choice depends on the local service and the suspected pattern of disease. Imaging can also help when a possible relapse is difficult to assess with blood markers. Arranging a test should not become a reason to delay urgent clinical care for concerning symptoms. [27]

Some services use temporal artery biopsy to help confirm giant cell arteritis. United States guidance places greater emphasis on biopsy in settings where specialist vascular ultrasound expertise is less established. This does not mean a patient must arrange both tests independently or that the methods answer every question equally well. A clinician chooses the pathway based on the suspected disease and available expertise, and may assess larger arteries too. Ask how the result will be interpreted if it is negative but concern remains. The important principle is timely assessment with a clear plan for unresolved uncertainty. [28]

Treatment goals and the course of illness

Glucocorticoids remain the usual initial treatment for PMR, with the aim of controlling inflammation while limiting treatment-related harm. Recent German, Austrian and Swiss recommendations emphasize individualized care and consideration of other illnesses when choosing treatment. A plan should therefore include more than a prescription: it should explain the expected improvement, monitoring, review arrangements and what would prompt reconsideration. A steroid-sparing medicine may be discussed when the likely benefits justify its additional risks and practical burden. The appropriate balance can change over time as symptoms, test results, side effects and the person’s priorities become clearer. [5]

There is no reliable finish date that applies to every person with PMR. An Olmsted County study following people diagnosed with PMR documented protracted glucocorticoid treatment and relapses, particularly earlier in treatment. Findings from one population and its treatment practices cannot predict an individual’s course. A longer treatment period should lead to continued assessment of benefit, harms and alternatives, rather than blame or a promise that the next reduction will definitely succeed. Ask how the team distinguishes a relapse from another painful condition and what contact route to use if familiar symptoms return. [18]

When steroid-sparing treatment is discussed

Methotrexate is one medicine specialists may consider to reduce reliance on glucocorticoids. A small randomized trial published in December 2025 studied recently diagnosed PMR and found steroid-free remission at one year more often with methotrexate than with placebo: 80% compared with 46% among the patients included in the analysis. The study supports a potential benefit, but its size, selected participants and trial protocol limit what it can promise for an individual. It does not establish that every new patient should receive methotrexate. Suitability, safety monitoring and the timing of treatment still require clinical judgment. [8]

Approval wording matters. In the United States, sarilumab is authorized for adults with PMR when corticosteroids have not worked adequately or a corticosteroid taper cannot be tolerated. The European indication addresses adults whose corticosteroid response has been inadequate or whose disease relapses during reduction. These are specific treatment situations, not a recommendation that everyone with PMR begin a biologic. Local access and prescribing decisions may add further requirements. The clinician should explain why the medicine fits the person’s circumstances and which alternatives were considered. [6]

Sarilumab blocks an inflammatory signalling pathway involving interleukin-6. In the SAPHYR trial, people whose PMR had relapsed during steroid reduction were assigned to sarilumab or placebo alongside different planned steroid-reduction programmes. Sustained remission at one year occurred in 28% and 10%, respectively, and the sarilumab group had lower cumulative steroid exposure. Those results show a benefit under the trial conditions, not guaranteed remission or a head-to-head ranking against every other option. Side effects and treatment discontinuations also occurred. The different steroid programmes are part of the comparison and should not be copied into a personal treatment plan. [7]

Sarilumab also requires safety screening and monitoring. Its label includes a serious-infection warning, tuberculosis assessment, blood-cell and liver-test monitoring, and attention to lipid changes. Some inflammatory signs may be reduced because interleukin-6 blockade suppresses acute-phase responses. Feeling unwell therefore deserves attention even if a familiar inflammation marker looks reassuring. Ask which symptoms require prompt contact and provide a complete medicine list, including nonprescription products. The label is a safety reference for the treating team, not instructions for independently starting, stopping or adjusting treatment. [6]

What other treatment studies tell us

Tocilizumab is another interleukin-6 receptor blocker studied in PMR. A randomized trial in people with active, glucocorticoid-dependent disease found better results on a combined disease-activity and steroid-reduction outcome than placebo. A combined endpoint is important to interpret carefully: meeting a trial definition does not necessarily mean every symptom has disappeared or that the medicine has no risks. The study adds evidence for specialist discussion of steroid-sparing treatment, while local authorization and individual suitability remain separate questions. Ask which evidence is relevant to the actual situation, such as persistent disease, repeated relapse or difficulty tolerating steroids. [10]

A separate, much smaller tocilizumab trial examined newly diagnosed PMR. It found more steroid-free remission during its study period than placebo, but only 36 people were randomized. This is a different patient group and a different study design from trials of established steroid-dependent disease. The distinction matters when comparing treatment headlines: a result in early disease cannot simply be transferred to years of recurrent symptoms. Nor does a research protocol establish a safe reduction schedule outside that study. A specialist can explain whether the evidence supports an option, what remains uncertain and how treatment would be monitored. [9]

The 2026 secukinumab evidence and regulatory position

The 2026 REPLENISH trial studied secukinumab, which targets interleukin-17A, in 381 people with recently relapsed PMR. Sustained remission at one year occurred in about 41% of each secukinumab group and about 20% of the placebo group. All groups also followed a trial steroid-reduction programme. Some infections and hypersensitivity reactions were more common with secukinumab. The findings expand the evidence for steroid-sparing approaches, but they do not establish superiority over sarilumab, methotrexate or tocilizumab because those medicines were not the comparators. Regulatory authorization, safety and access require separate consideration from the trial result. [11]

As of 9 October 2026, a regulatory update also needs careful wording. On 17 September, the European Medicines Agency’s committee issued a positive opinion recommending a PMR indication for secukinumab. The published opinion says updated product information will follow a European Commission decision. A committee recommendation is not itself proof that that authorization has been granted. It also does not establish approval in another country. Readers encountering a headline about a new treatment should check the final local indication and access arrangements with their specialist, rather than assuming that publication of a trial or opinion makes the medicine available for them. [12]

Protecting bone health and reducing infection risks

Bone protection should be discussed early when longer-term glucocorticoid treatment is expected. Guidance recommends assessing fracture risk and considering bone-density and vertebral assessment as appropriate, rather than waiting for a fracture to occur. Previous fractures, falls, existing bone disease and other medicines can influence that assessment. Nutrition, calcium and vitamin D needs, and protective medicines should be considered individually. More supplements are not automatically better, and a specific bone medicine is not right for everyone. Ask who is responsible for this part of care and when the plan will be reviewed as steroid exposure changes. [23]

Infection vigilance remains important throughout steroid treatment. A large English study of people with PMR or giant cell arteritis found associations between oral glucocorticoid exposure and infection, including at relatively low exposure. Because it was observational, it cannot separate every effect of the medicine from the illness and other health factors. It nevertheless supports discussing infection risk rather than assuming a smaller prescription has no risks. Ask which symptoms should trigger same-day advice and how to contact the service outside office hours. Tell any clinician assessing a new illness about current and recent steroid use. [24]

Vaccination belongs in the treatment discussion because some PMR medicines affect immune responses and infection risk. Rheumatology vaccination guidance considers the vaccine, the medicine and the person’s circumstances together; recommendations about live vaccines differ from those for non-live vaccines. Bring an available vaccination record and ask which locally recommended vaccines are appropriate and when. Do not delay or interrupt a prescription to improve vaccine response without instructions from the treating team. The plan also needs to reflect current national advice, since a general rheumatology guideline does not replace updates to seasonal or newly introduced vaccination programmes. [31]

Travel plans deserve an early medication and vaccination check. Immune suppression can alter vaccine effectiveness and the safety of some live vaccines, while different medicines create different considerations. Give the travel clinician the actual drug list and treatment history rather than saying only that PMR is stable. Destination-specific advice may also depend on other health conditions and timing. A vaccine that was suitable before treatment may need a different discussion now. Avoid independently holding medication for a trip or assuming that all vaccines are unsuitable; the relevant professionals can coordinate a plan based on the exact circumstances. [33]

Making medicine safety part of ordinary follow-up

A complete medication review helps prevent avoidable problems. Include prescriptions, painkillers bought without a prescription, vitamins, herbal products and medicines supplied by another clinician. Prednisone information advises discussing other medicines and supplements, relevant health conditions, and planned procedures with the prescriber or pharmacist. Ask how blood pressure and blood glucose will be checked, and report mood changes, sleep difficulties or eye symptoms. The exact product and instructions matter. If a label, clinic letter and remembered advice seem inconsistent, request clarification before making a change. Bring the current packages or an accurate list to appointments. A written plan is especially helpful when more than one team is involved or when a family member assists with medicines. [32]

Some treatment effects are important even when routine blood tests are satisfactory. Interviews with people taking glucocorticoids for PMR or giant cell arteritis described concerns about bruising, appearance and weight changes, alongside uncertainty and the work involved in managing treatment. A small qualitative study cannot tell us how common each problem is, but it identifies concerns worth making room for in consultations. Mention the effects that interfere with confidence, sleep, relationships or daily routines. They can inform a discussion of options and support, rather than being treated as an unavoidable price that must remain unspoken. [30]

Long-term glucocorticoid treatment can suppress the body’s own cortisol production. That creates a separate safety issue from whether PMR is active, and recovery varies between people. Withdrawal symptoms, adrenal insufficiency and returning inflammation can overlap, so an internet symptom checklist cannot safely choose between them. Do not abruptly stop prescribed steroids or change a reduction plan independently. Ask the treating team for written instructions about illness, vomiting, surgery and whom to contact, and whether an emergency steroid card or equivalent is appropriate locally. Severe illness with collapse, confusion or inability to keep medicine down requires urgent medical help. [22]

Supporting movement and independence

Movement can support general health, strength and function, but activity should match current ability. World Health Organization guidance encourages people with health limitations to adapt activity and seek advice when needed. For someone whose movement is painful or restricted, a clinician or physiotherapist can help choose a manageable starting point and review progress. Avoid judging success against another person’s walking distance or exercise routine. A gradual return to meaningful activities may be a more useful goal than reaching a generic target immediately. Exercise supports wellbeing; it does not establish that PMR inflammation is controlled or replace prescribed treatment. [35]

If stiffness, weakness or dizziness makes moving around less secure, falls deserve their own assessment. NICE guidance for older adults and others at increased risk considers previous falls, walking and balance, medicines and hazards at home. This is broader health guidance, not evidence that every person with PMR has the same risk. Explain near-falls as well as actual falls, and mention difficulties getting out of a chair or using the bathroom safely. A tailored review may identify practical changes or rehabilitation support. Staying independent is a reasonable care goal, but it should not require ignoring a new safety problem. [34]

Tracking function can be more informative than trying to give stiffness a perfect number. Focus-group research found that people often explained stiffness through the activities it prevented and the way it changed their day. A short record might note whether dressing, reaching a shelf, climbing stairs or walking to the shops is easier or harder than before. Add when the difficulty occurs and whether pain, stiffness or tiredness seems most limiting. This creates useful material for a consultation without turning the diary into a test that decides medication changes. Choose a few meaningful activities rather than recording every movement. [40]

Food, complementary approaches and realistic expectations

There is no reason to turn general nutrition advice into a promise that a special diet cures PMR. World Health Organization guidance supports a varied eating pattern that includes vegetables, fruit, pulses, whole grains and suitable protein sources, while limiting excess salt and free sugars. Individual needs may differ with appetite changes, diabetes, kidney disease or other conditions. Discuss persistent weight loss, difficulty preparing food or trouble eating enough rather than starting a restrictive programme automatically. A dietitian can help when needed. Food choices support overall health and should fit the person’s circumstances and treatment plan. [36]

People with PMR sometimes try dietary changes, exercise approaches or complementary products alongside medical care. A primary-care cohort recorded such self-management choices, but observing that people used an approach does not show that it reduced inflammation or allowed safer steroid withdrawal. Keep a record of what is being used and discuss it with a pharmacist or clinician, especially if a product contains several ingredients. An online testimonial cannot account for simultaneous treatment changes or the natural variation in symptoms. Be particularly cautious about any claim that a supplement makes professional monitoring or prescribed treatment unnecessary. [25]

Fatigue, sleep and the wider effect of PMR

Fatigue and poor sleep may persist even when measured disease activity is low. A small study following people with PMR over time found ongoing fatigue and functional difficulties in some participants despite treatment. These experiences deserve attention, but fatigue alone cannot identify active PMR or justify a medication increase. Describe sleep quality, the time of day tiredness is worst and what it prevents. The care team can consider the wider picture and decide whether further assessment or support is needed. Recovery should include the ability to take part in daily life, not only improvement in laboratory results. [17]

Researchers developing a PMR impact measure identified four useful areas: symptoms, function, emotional wellbeing and steroid side effects. These domains offer a practical way to prepare for follow-up without reproducing a questionnaire or turning it into a home diagnostic tool. Consider what has improved, what remains difficult and what has changed since the last visit in each area. A lower pain score can coexist with poor sleep or unacceptable treatment effects. Bringing that information helps the team assess the overall balance of care. No single score should be used independently to decide that a flare has occurred. [39]

Preparing for later reviews and the end of treatment

Symptoms after a planned end to steroid treatment need interpretation rather than an automatic restart. In a study of people with PMR or giant cell arteritis after prednisolone cessation, symptoms compatible with adrenal insufficiency were more frequent than confirmed biochemical adrenal insufficiency. That difference illustrates why symptoms alone cannot establish either hormone deficiency or returning PMR. The study does not justify dismissing someone who feels unwell or testing everyone in the same way. Agree in advance who to contact if symptoms recur after treatment ends, and make sure any urgent illness is assessed promptly. [26]

A useful appointment ends with a plan that can be explained in ordinary language. Ask what diagnosis is most likely, what remains uncertain, what each treatment is meant to achieve and how its benefits and harms will be checked. Agree who will communicate test results, when the next review is due and which symptoms require earlier contact. Bring the questions that matter most to daily life, and ask for a written summary if remembering details is difficult. A family member, interpreter or other chosen supporter can help when wanted. Decisions can be revisited as circumstances and evidence change. [37]